

Mark Elliott Murphy M.D., FACP, AGAF
CURRICULUM VITAE

ADDRESSES

Office:

Center for Digestive and Liver Health
1139 Lexington Avenue
Savannah, GA 31404
Phone: (912) 303-4200
Fax: (912) 790-2701

CERTIFICATION AND LICENSURE

Diplomate, National Board of Medical Examiners
Diplomate, American Board of Internal Medicine
(September 25, 1991; recertified 12/21/03)
Diplomate, American Board of Internal Medicine; Gastroenterology
(November 3, 1993; recertified 12/28/03)
License to practice medicine:
State of Georgia
State of South Carolina
State of North Carolina

POSTGRADUATE EDUCATION

Fellowship, Digestive Diseases and Nutrition

University of North Carolina at Chapel Hill
Chapel Hill, NC
July 1, 1991 – June 30, 1994

Residency, Internal Medicine

University of North Carolina at Chapel Hill
Chapel Hill, NC
July 1, 1989 – June 30, 1991

Internship, Internal Medicine

The University of North Carolina at Chapel Hill
Chapel Hill, NC
July 1, 1988 – June 30, 1989

MEDICAL EDUCATION

Medical College of Georgia
August 1984 – June 1988
Doctor of Medicine awarded June 4, 1988
Augusta, Georgia

Mark Elliott Murphy M.D., FACP, AGAF
CURRICULUM VITAE

UNDERGRADUATE EDUCATION

University of Georgia Athens, Georgia
Summa cum laude
First Honor Graduate
September 1980 – June 1984
Bachelor of Science in Zoology awarded June 9, 1984

FACULTY APPOINTMENTS

Associate Clinical Professor of Medicine
Department of Internal Medicine
The Medical College of Georgia
Augusta, Georgia
May 1, 2000-present

Assistant Professor
Department of Internal Medicine
Mercer University School of Medicine – Savannah Campus
Macon, Georgia
February 26, 1997 - present

Assistant Clinical Professor
Department of Internal Medicine
The Medical College of Georgia
Augusta, Georgia
May 1, 1996 – May 1, 2000

Clinical Instructor of Medicine
Division of Digestive Diseases and Nutrition
The University of North Carolina at Chapel Hill
July 1991-June 1994

EMPLOYMENT EXPERIENCE

Founding Physician
Center for Digestive and Liver Health, LLC
Savannah, Georgia
January, 2001-present (Managing Partner 1/01-3/03)

Founding Physician, Savannah Center for Digestive and Liver Diseases
Savannah, Georgia
July 1994 – December, 2000 (Managing Partner 7/94-12/00)

President and Board Chairman
Southeastern Digestive and Liver Disease Research Institute, P.C.

Mark Elliott Murphy M.D., FACP, AGAF
CURRICULUM VITAE

Savannah, Georgia
November, 1998-present

Chief, Division of Gastroenterology
Memorial Medical Center
Savannah, Georgia
January 1996 – December 1997

Chief of Gastroenterology Education
Internal Medicine Residency Program
Memorial Medical Center
Savannah, Georgia
January 1998 – present

Physician Consultant
Medical Review of North Carolina
March 1992 – June 1994
Independent Contractor

Coastal Emergency Services
Contract Physician
Durham, North Carolina
January 1991 – July 1994

PROFESSIONAL SOCIETY MEMBERSHIPS

American Medical Association
American College of Physicians (Fellow)
American Society for Gastrointestinal Endoscopy
American Gastroenterological Association (Fellow)
American College of Gastroenterology
Georgia Gastroenterology Society
Crohn's and Colitis Foundation of America
Georgia Medical Society
American College of Physician Executives
American Association for the Study of Liver Diseases
American Liver Foundation (Georgia Medical Advisory Committee)

MAJOR COMMITTEE ASSIGNMENTS/BOARD MEMBERSHIPS

Chairman, Professional Affairs Committee, Memorial Health, 2008-present
Member, Mercer University School of Medicine Dean's Selection Committee, 2008-2009
Member, Mercer University School of Medicine Admissions Committee, 2008-2009
Chairman, Membership and Privileges Committee, Memorial Health, 2006-2008
Board Member, Franklin College of Arts & Sciences, University of Georgia, 2005-present
Committee Member, Heizer-Bozymski Chair in Digestive Diseases, UNC-Chapel Hill, 2005
Member, Memorial Physician/CEO Council, 2003-2008

Mark Elliott Murphy M.D., FACP, AGAF
CURRICULUM VITAE

Participant, Memorial Physician Leadership Academy, 2004-2005
Member, Board of Directors, Memorial Health University Medical Center, 2004-present
Member, Board of Directors, Medical College of Georgia Alumni Association, 2004-present
Chairman, Department of Internal Medicine, Memorial Health University, 2006-2007
Vice Chairman, Department of Internal Medicine, Memorial Health University Medical Center, 2004-2005
Chairman, Internal Medicine Outcomes and Performance Committee, Memorial Health University Medical Center, 2004-2005
Member, Board of Directors, Memorial Health Trust, 2001-2004
Chairman, Subcommittee on Education, Memorial Health University Medical Center, 2000
Member, Memorial Internal Medicine Program Director Selection Committee, 1999
Member, Board of Directors, Memorial Physicians' Practice Group, 1999-2000
Medical Care Evaluation Committee, Candler-St. Joseph's Health System, 1999-present
Medical Director, Crohn's and Colitis Foundation Clinical Research Site, Savannah, GA
Medical Director, Gastrointestinal Diagnostic Unit, Memorial Medical Center, 1998-99
Member, State Medical Advisory Board, Crohn's and Colitis Foundation of Georgia, 1998-99
Committee on Education / Curriculum, Memorial Medical Center, 1/98 – present
CME Committee, Candler Hospital, 1/97 – present
Institutional Review Board, Candler Hospital, 1/97 – 12/2003
Section Chief, Gastroenterology, Memorial Medical Center, 1/96 – 12/97
Medical Care Evaluation Committee, Memorial Medical Center, 1/95 – 12/96
GIDU Committee, Memorial Medical Center, 7/94 – present

HOSPITAL AFFILIATIONS

Memorial Health University Medical Center, Savannah, Georgia
Candler General Hospital, Savannah, Georgia
St. Joseph's Hospital, Savannah, Georgia
Liberty Regional Medical Center, Hinesville, Georgia

AWARDS AND HONORS

2009-2010 CCFA IBD Preceptorship Award (one of 12 in the U.S.)
2009 Patients' Choice Recognition
2009-2010 Inclusion in "Best Doctors in America"
2007 AMA Physician Recognition Award with Commendation
2007-2008 Inclusion in "Best Doctors in America"
2005-2006 Inclusion In "Best Doctors in America"
2005 AMA Physician Recognition Award with Commendation
2003 Inclusion in "America's Top Doctors"
2002 and 2004 Finalist for Physician of the Year, Memorial Health University Medical Center
2001 AMA Physician Recognition Award with Commendation
2001 Finalist for Georgia Crohn's and Colitis Foundation Premier Physician Award
Strathmore Who's Who in Medicine, Lifetime Member, 1999
Attending of the Year, Memorial Medical Center Medicine Residency Program, 1998

Mark Elliott Murphy M.D., FACP, AGAF
CURRICULUM VITAE

1997 AMA Physician Recognition Award with Commendation
Henry C. Fordham Award, 1989 (Outstanding Resident at UNC)
Cited for Honors Boards Scores on NBME Parts I, II and III
Outstanding Young Men of America, 1988 – 1998 (Nominations Board 1996 – 98)
Alpha Omega Alpha (AOA), elected as a junior; chapter vice president
Merck Manual Award (top 5 academically in medical school class), 1988
MCG Alumni Academic Scholarship, 1984 – 1988
Phi Kappa Phi National Graduate Fellowship, 1984
University of Georgia First Honor Graduate, 1984 (equivalent to valedictorian;
finished with 4.0 GPA on a 4.0 scale)
Graduation from UGA with General Honors and with Distinction in Zoology for
Independent Research, 1984
Dean William Tate Scholar (Outstanding Senior at the University of Georgia), 1984
Phi Beta Kappa (only junior student selected at the University of Georgia in 1983)
Jasper Dorsey Award (Outstanding Junior Man at UGA), 1982
Hamilton McWhorter Award (Outstanding UGA Freshman), 1981
National Merit Scholar
President's Award ("for outstanding contributions as a student at the UGA")
Blue Key Honor Society
Omicron Delta Kappa Honor Society
Who's Who Among Students at American Colleges and Universities
Mortarboard Honor Society
National Golden Key Scholarship Recipient
Lee B. Sayre Poetry Award
Class Rankings: Medical School: 2nd out of 180
Undergraduate: 1st out of 4400

RESEARCH EXPERIENCE

Honors Thesis

"The effect of phytoplankton-derived photosynthetic exudates on bacterial secondary production in estuarine waters of the Georgia coast."

Completed in June 1984 under the direction of James W. Porter, Ph.D. (professor of Zoology, the University of Georgia) and Roger B. Hanson, Ph.D. (assistant professor of Marine Microbiology, Skidaway Institute of Oceanography)

Clinical Trials

Sub Investigator on Abbott Laboratories-sponsored clinical trial, "Long-term safety and efficacy of Zileuton in patients with ulcerative colitis in remission," 1991-1993

Sub Investigator (medical consultant) on Glaxo Ondansetron/Placebo Project Protocol S3A341, "Use of Ondansetron in the treatment of social phobia," 7/92-12/92

Mark Elliott Murphy M.D., FACP, AGAF
CURRICULUM VITAE

Sub Investigator on Synergen Laboratories-sponsored clinical trial, "A randomized, double-blind, placebo-controlled multicenter study of human recombinant interleukin-1 receptor antagonist in patients with ulcerative colitis (Protocol #0507)," 1992-1993

Sub Investigator (medical consultant) on SmithKline clinical trial, "The use of Paroxetine in panic attacks," 1/93-6/94

Principal Investigator, Bio-Pharm/TAP clinical trial "The use of lansoprazole in treatment of *Helicobacter pylori*," 9/95-5/96

Sub Investigator, "The use of 4-ASA in the treatment of mild to moderate Crohn's disease of the small intestine," 6/96-3/98

Principal Investigator, Orphan Medical Trial OMC-SCFA-1, "A randomized, double-blind, placebo-controlled trial of Colomed, a short-chain fatty acid rectal enema in the treatment of radiation-induced proctitis and proctosigmoiditis," 10/96-10/97

Sub Investigator, Metabolic Solutions Trial, "An investigation of a blood test (EZ HBT--*Helicobacter* Blood Test) for Diagnosis of active *H. pylori* infection," 4/97-7/99

Principal Investigator, Schering-Plough Protocol R96-418, "Intron A + Ribavirin for Treatment of Patients with Interferon-Refractory or Interferon-Relapsed Chronic Hepatitis C," 5/97-7/98

Principal Investigator, Boehringer Mannheim Protocol MF 4417, "Multicenter, controlled, randomized, open study on the safety and efficacy of BM 80.1003 alone and in combination with interferon in comparison with interferon monotherapy and untreated control during six months of active therapy and six months of post-treatment observation in patients with chronic hepatitis B," 5/97-1/98

Principal Investigator, TAP Holdings Protocol M96-619, "A study to evaluate the effects of lansoprazole 30mg or 15mg QD versus placebo in patients with non-ulcer dyspepsia," 5/97 – 2/98

Principal Investigator, Schering-Plough Study, "Intron-A + Ribavirin for patients with interferon-naïve chronic active hepatitis C," 8/97 – 10/98

Principal Investigator, Glaxo-Wellcome Protocol S3BA3001, "A 12-week randomized, double-blind, placebo-controlled study of alosetron on female patients with irritable bowel syndrome," 9/97-8/98

Principal Investigator, Astra-Merck study, "Multicenter randomized double-blind 8-week comparative efficacy and safety study of H199/18 40mg and omeprazole 20mg in study subjects with erosive esophagitis," 9/97-3/98

Mark Elliott Murphy M.D., FACP, AGAF
CURRICULUM VITAE

Principal Investigator, Astra-Merck study, “Multicenter open-label long-term safety study of H199/18 40mg in subjects with healed erosive esophagitis,” 9/97-9/98

Principal Investigator, Glaxo-Wellcome Protocol S3BA3003, “A twelve-month randomized, double-blind, placebo-controlled study to evaluate the quality of life and safety associated with the long-term use of alosetron (GR68755) in subjects with irritable bowel syndrome,” 11/97-8/98

Principal Investigator, Cell Pathways, Inc. Clinical Trial, “A randomized, multicenter, dose-response, double-blind, placebo-controlled study to determine the efficacy in causing polyp regression and the safety of FGN-1 in patients with sporadic adenomatous polyps of the colon,” 3/98-9/00

Recipient of unrestricted grant by Schering-Oncology Biotech, “Intron A + Ribavirin + Amantadine versus Intron A + Ribavirin for treatment of patients with chronic hepatitis C not previously treated with interferon: a randomized trial.” (original research-pilot study) September, 1998-present

Principal Investigator, “Use of Infergen in Hepatitis C patients who have not responded to Interferon/Ribavirin.” Amgen, Inc. protocol #980170, March, 1999-July 2000

Principal Investigator, “A randomized, double-masked, placebo-controlled study of subcutaneously administered rh IL-11 in patients with active Crohn’s disease not treated with prednisone.” Genetics Institute C9853-14, July 1999 – April 2001

Principal Investigator, “A 24-week randomized, open-label study of health care resource use, quality of life, and productivity with alosetron 1 mg twice daily versus traditional therapy in females with non-constipated irritable bowel syndrome (S3B30020).” Glaxo-Wellcome, December 1999 – October 2000

Principal Investigator, “An observational study to assess prevalence, natural history, and burden of illness of IBS in clinical practice and to evaluate the impact of alosetron treatment on natural history and burden of illness on a cohort of females whose predominant bowel symptom is diarrhea.” Glaxo Wellcome # S3B40032, March 2000-October 2000

Principal Investigator, “Retrospective Review of Ischemic Colitis in Gastroenterology and Multi-Specialty Practices over a 5-Year Period.” Sponsored by Glaxo Wellcome, June 2000

Principal Investigator, “Prevention of Sporadic Colorectal Adenomas with Celecoxib.” Kendle Searle Protocol IQ4-99-02-005. In conjunction with the National Cancer Institute Protocol No. 1CN-95015, April 2000-present

Sub Investigator, “Comparative Efficacy Study of Esomeprazole Magnesium (40 mg QD) and Lansoprazole (30 mg QD) in Patients with Erosive Esophagitis.” Astra-Zeneca Protocol 267, July 2000 – December 2000

Mark Elliott Murphy M.D., FACP, AGAF
CURRICULUM VITAE

Principal Investigator, “Comparison of PEG-interferon alfa-2b plus ribavirin given as fixed dose or on a weight-optimized basis for the treatment of chronic hepatitis C in previously untreated adult subjects.” Schering Oncology Biotech IND #9243, April 2001-present

Principal Investigator, “Dose Comparison Study of PEG-Interferon alfa 2b + ribavirin for patients with chronic hepatitis C who have not responded to standard interferon + ribavirin.” Schering Oncology Biotech IND #9243, June 2001-present

Principal Investigator, “Clinical Efficacy and Safety of Mesalamine Rectal Gel vs Placebo in the Treatment of Mild to Moderate Distal Ulcerative Colitis: A Multicenter, Double-blind, Randomised and Parallel Groups Study.” Protocol ASGELUC 02-03, 2003

Principal Investigator, “A double-blind, randomized, placebo-controlled, dose-ranging study to assess safety, efficacy, and tolerance of TAK-370 in subjects with GERD with predominant regurgitation.” Protocol 01-01-TL370-001, Takeda Pharmaceuticals, 2003.

Principal Investigator, “A Multicenter Comparison of the Exact Panel with Hemocult II for the detection of colorectal cancer in average risk patients.” EXACT Corporation, Protocol 2001-01, 2001-2002.

Principal Investigator, “Long-term follow-up with the option of open-label re-treatment of ulcerative colitis with interferon beta-1a for patients who completed previous protocols using IFN-beta-1a.” Serono Corporation, 2002.

Principal Investigator, “A multicenter, randomized, double-blind, placebo-controlled study of the human anti-TNF monoclonal antibody adalimumab for the induction of clinical remission in subjects with Crohn’s disease.” Protocol M02-403, 2003.

Principal Investigator, “A randomized, double-masked, placebo-controlled study of subcutaneously-administered human IL-11 in patients with Crohn’s disease not treated with prednisone.” Wyeth C9853-14, 2002.

Principal Investigator, “A multicenter, randomized, placebo-controlled study of the human anti-TNF antibody adalimumab for the maintenance of clinical remission in subjects with Crohn’s disease.” M02-433, 2003.

Principal Investigator, “A multicenter, double-blinded study in patients with compensated cirrhosis due to hepatitis C who are non-responders to prior interferon-based therapy, comparing treatment with Thymosin alpha 1 + PEG interferon alpha 2a with PEG interferon alpha 2a plus placebo.” SciClone TA1-CHC-2K0804, 2003-2004.

Principal Investigator, “A multicenter, double-blinded study in non-cirrhotic patients with hepatitis C who are non-responders to prior interferon-based therapy comparing PEG alpha 2a + Thymosin alpha 1 with PEG alpha 2a + placebo.” SciClone Ta1-CHC-2K0803a, 2003.

Mark Elliott Murphy M.D., FACP, AGAF
CURRICULUM VITAE

Principal Investigator, “A double-blind, placebo-controlled, randomised, multicenter study to investigate the safety and efficacy of cilansetron over 12 weeks followed by a 4-week re-randomised treatment period in diarrhea-predominant IBS.” Solvay Protocol S2413011, 2003.

Principal Investigator, “Multicenter, randomized, double-blind, double-dummy, parallel-group comparison of the remission rates for once-daily treatment with esomeprazole 20 mg and lansoprazole 15 mg for 6 months in patients whose EE was healed.” Astra Zeneca #325, 2003.

Principal Investigator, “Multicenter, randomized, double-blind, double-dummy, parallel-group efficacy study comparing 8 weeks of treatment with esomeprazole 40 mg to lansoprazole 30 mg for healing of erosive esophagitis.” Astra Zeneca #322, 2003.

Principal Investigator, “Multi-center trial of topical nitroglycerine ointment in anal fissures.” Cellegy protocol CP 125 03-02-01, 2003.

Principal Investigator, “A multi-center, randomized, double-blind, placebo-controlled study to determine the safety and efficacy of pravastatin 80 mg in hypercholesterolemic patients with chronic, well-compensated liver disease.” 2003-2004.

Principal Investigator, “A phase III multinational, multi-center, double-blind placebo-controlled parallel-group 26 week study to assess the safety and efficacy of the humanized anti-TNF PEG conjugate CDP870, 400 mg SC in the treatment of patients with active Crohn’s disease.” Protocol CDP870-031, 2004-2006.

Principal Investigator, “A phase III, multi-center, open-label, 52-week safety study to assess the safety of chronic therapy with the humanized anti-TNF PEG conjugate CDP 870, 400 mg SC, dosed 4-weekly to week 48, in the treatment of patients with active Crohn’s disease who have previously completed studies CDP870-031 or CDP 870-032.” Protocol CDP870-033, 2004-2007.

Principal Investigator, “A randomized, double-blind, placebo-controlled multicenter study to assess the safety, efficacy and tolerability of tegaserod alone and in combination with omeprazole given orally in patients suffering from non-erosive GERD.” 2004-2005.

Principal Investigator, “A 6-week, randomized, double-blind, placebo-controlled multi-center study to assess the efficacy and safety of oral tegaserod (6 mg po bid) in female patients with dyspepsia.” Protocol CHTF919D2301. 2004-2005.

Principal Investigator, “A phase 3, multicenter, randomized, double-blind, parallel-arm, 52-week dose comparison study of the efficacy and safety of 25 mg QD and 50 mg QD of OPC-6535 oral tablets and 800 mg bid of Asacol in the maintenance of remission in subjects with ulcerative colitis.” Protocol 197-02-220, 2004-2006.

Mark Elliott Murphy M.D., FACP, AGAF
CURRICULUM VITAE

Principal Investigator, “A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-arm study of the efficacy and safety of OPC-6535 tablets in the treatment of subjects with active ulcerative colitis.” Protocol 197-02-218, 2005-2006.

Principal Investigator, “A multicenter, randomized, double-blind, active-controlled trial comparing Remicade and Remicade plus azathioprine in the treatment of patients with Crohn’s disease naive to both immunomodulators and biologic therapy (SONIC).” Protocol C0168T67, 2005-2007.

Principal Investigator, “A randomized, placebo-controlled study to evaluate the effect of a probiotic on maintenance of remission of Crohn’s disease.” 2005-2006.

Principal Investigator, “A phase 3, randomized, placebo-controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe ulcerative colitis,” Millennium 2006-2008.

Principal Investigator, “A multinational, multicenter, double-blind, randomized parallel group study to compare the safety and efficacy of 200 mg PAR-101 taken q 12h with 125 mg Vancomycin taken q6h for ten days in subjects with *Clostridium difficile*-associated diarrhea.” Optimer Protocol 101.1.C, 2006-2009.

Principal Investigator, “A multi-center, open-label treatment protocol of the anti-TNF monoclonal antibody adalimumab in patients with moderate to severe Crohn’s disease with previous exposure to Infliximab.” Protocol M06-808, 2006-2007.

Principal Investigator, “A double-blind, randomized, 6-week, parallel-group clinical trial to assess the safety and efficacy of Asacol 4.8 gm/day (800 mg mesalamine tablet) versus Asacol 2.4 gm/day (400 mg mesalamine tablet) for the treatment of moderately active ulcerative colitis (ASCEND III)” P&G protocol 2006444, 2007.

Principal Investigator, “A Phase 2/3 multicenter, randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of golimumab induction therapy, administered subcutaneously, in subjects with moderately severe ulcerative colitis.” Protocol C0524T17/18, 2007-2009.

Principal Investigator, “A Phase 3 study of 2 dose regimens of telepravir in combination with peginterferon alpha-2a and ribavirin in treatment-naïve subjects with genotype 1 chronic hepatitis C.” Vertex Pharmaceuticals VX 950-108, 2008-2009.

Principal Investigator, “A phase 3, randomized, placebo-controlled, blinded, multicenter study of the induction and maintenance of clinical response and remission by MLN0002 in patients with moderate to severe Crohn’s disease.” 2006-2008.

Mark Elliott Murphy M.D., FACP, AGAF
CURRICULUM VITAE

Principal Investigator, “A phase IIIb multi-center, double-blind, placebo-controlled, randomized trial to examine to corticosteroid-sparing effect of certolizumab pegol in patients with moderate to severe Crohn’s disease (COSPAR I).” UCB Protocol C87059, 2006-2008.

Principal Investigator, “An open-label, multi-center trial to examine the long-term safety, efficacy and steroid-sparing effect of certolizumab pegol in patients with moderate to severe Crohn’s disease who have failed tapering of corticosteroids, needed corticosteroids after completion of tapering, or have successfully completed the trial C87059. (COSPAR II).” UCB Protocol 87065, 2006-2008.

Principal Investigator, “ A Phase III study to demonstrate the efficacy and safety of RG1068-enhanced magnetic resonance cholangiopancreatography (MRCP) in the evaluation of subjects with a history of acute or acute recurrent pancreatitis.” Repligen RG 1068-16, 2008-2009.

Principal Investigator, “A Phase 2, randomized, double-blind, parallel-group, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics and activity of GS 9459 in adults with NASH.” Gilead, 2009.

Basic Science Research

Ongoing research with R. Balfour Sartor, M.D. (Professor of Medicine, Division of Digestive Diseases and Nutrition, The University of North Carolina at Chapel Hill) on inflammatory bowel disease (Crohn’s and ulcerative colitis), with an emphasis on cellular/cytokine interactions (November 1990-present; multiple projects)

PUBLICATIONS

Abstracts

Sartor RB, Bender DE, Murphy ME, McCall RD, Thompson RC. Prevention and treatment of experimental enterocolitis with a recombinant IL-1 receptor antagonist. *Gastroenterology* 1991; 100 (5), A613.

Holt LC, Bocker U, Damiao A, Murphy M, Haskill JS, Sartor RB. Decreased ratio of IL-1RA/IL-1 mRNA is the result of inflammation rather than a unique IBD-related abnormality. *Gastroenterology* 1997; 112 (4), A998.

Waller AD, Murphy ME. Resolution of inflammatory hepatic pseudotumor after spontaneous drainage through the anterior abdominal wall. *Hepatology* 1997; 26 (4), 625A.

Mark Elliott Murphy M.D., FACP, AGAF
CURRICULUM VITAE

Non-Refereed Journals

Sartor RB, Murphy ME. Cytokines in inflammatory bowel disease. *The Regulatory Peptide Letter*, Volume IV, No. 4, 1993.

Murphy ME. Heartburn and Cancer: Am I At Risk? *Savannah Health Perspective*, Vol 4, #4, 2008.

Book Chapters

Sartor RB, Murphy ME, Rydzak E. Miscellaneous structural and inflammatory diseases of the colon (Chapter 80). *in* Textbook of Gastroenterology, second edition; Yamada T (ed). J.B. Lippincott, Philadelphia, 1995; pp1806-1832.

Murphy ME, Drossman DA. Anorexia nervosa, bulimia nervosa and the rumination syndrome: the eating disorders (Chapter 126). *in* Primary Care and General Medicine, first edition; Noble J (ed). Mosby-Yearbook, Inc., St. Louis, 1996.

Sartor RB, Murphy ME, Rydzak E. Miscellaneous structural and inflammatory diseases of the colon. *in* Textbook of Gastroenterology, third edition; Yamada T (ed). J.B. Lippincott, Philadelphia, 1999.

Murphy ME. "The Clinician's Companion III: A Guideline for Treatment of Hepatitis C" (contributor), 1999.

Murphy ME. "Boerhaave's Syndrome." *Emedicine Online Textbook in Internal Medicine*, 2000.

Murphy ME. "The Clinician's Companion IV: A Guideline for the Treatment of Hepatitis C" (contributor), 2000.

Sartor RB, Murphy ME, Rydzak E. Miscellaneous structural and inflammatory diseases of the colon *in* Textbook of Gastroenterology, third edition; Yamada T (ed). J.B. Lippincott, Philadelphia, 2003.

EDITORIAL BOARDS

Reviewer for *Mayo Clinic Proceedings*

SPEAKER'S BOARDS

Takeda
Astra-Zeneca
Schering
Shire

Mark Elliott Murphy M.D., FACP, AGAF
CURRICULUM VITAE

UCB

Procter and Gamble

PRESENTATIONS (Conferences and Invited Presentations Only)

Murphy ME. "Von Hippel-Lindau Syndrome." Clinical Pathologic Conference, The University of North Carolina at Chapel Hill, November 23, 1993.

Murphy ME. "A case of multiple pancreatic cysts." Gastroenterology Fellows' Conference of the Carolinas, Wilmington, NC, April 16-17, 1994.

Murphy ME. "A case of multiple pancreatic cysts: the Von Hippel-Lindau syndrome." Medical Grand Rounds, Memorial Medical Center, Savannah, GA, September 1994.

Murphy ME. "Current ideas on the etiology and pathogenesis of inflammatory bowel disease." Medical Grand Rounds, Memorial Medical Center, Savannah, GA, February 17, 1995.

Murphy ME. "Medical therapy for inflammatory bowel disease." Course Faculty, Medical College of Georgia Update on Gastroenterology and Hepatology, Savannah, GA, September 9, 1995.

Murphy ME. Course director for the First Annual Southeastern Inflammatory Bowel Disease Conference, Memorial Medical Center, Savannah, GA, December 9, 1995.

Murphy ME. "Food Poisoning." Course faculty, Summer Emergencies Conference, Candler Hospital, Savannah, GA, May 17, 1996.

Murphy ME. Course director for the Second Annual Southeastern Gastroenterology Symposium, "Advances in Gastroenterology," Savannah, GA, October 4-6, 1996.

Murphy ME. "Colorectal Cancer: Symptoms, Signs, Detection, Therapy and Prognosis." Colorectal Cancer Symposium, St. Joseph's Hospital, Savannah, GA, November 7, 1996.

Holt LC, Murphy ME, et al. "Decreased ratio of IL-1RA to IL-1 is the result of inflammation rather than a unique IBD-related abnormality." Digestive Disease Week Poster Sessions, Washington, D.C., May 13, 1997.

Murphy ME. Medical Director, Roche Biomedical Conscious Sedation Preceptorship. Memorial Medical Center, Savannah, GA. July-December, 1997.

Murphy ME. "The Hepatitides" Infectious Disease Update Symposium 1998, Savannah, Georgia, March 6, 1998.

Murphy ME. Course Director, "Inflammatory Bowel Disease: A Symposium for Patients, their Families and their Physicians." Savannah, GA, March 7, 1998

Mark Elliott Murphy M.D., FACP, AGAF
CURRICULUM VITAE

Murphy ME. "Etiology and Pathogenesis of Inflammatory Bowel Disease." Inflammatory Bowel Disease Symposium, Savannah, GA, March 7, 1998.

Murphy ME. "Hepatitis." The "Battle of the Bugs" Symposium, sponsored by the Association for Professionals in Infection Control (APIC), September 9, 1998.

Guest lecturer, Armstrong Atlantic State University graduate course in Womens' Health, "Current Topics in Womens' Gastrointestinal Health." October 6, 1998.

Murphy ME. "Treatment of Hepatitis C." Hepatitis C Seminar, Memorial Medical Center, Savannah, Georgia, Jan 23, 1999.

Murphy ME. "Emerging Treatments of Inflammatory Bowel Disease." CCFA IBD Symposium, Savannah, GA, March 6, 1999.

Murphy ME. Moderator, Annenberg IBD Symposium, Savannah, GA; March 6, 1999.

Murphy ME. "Clinical Manifestations in Inflammatory Bowel Disease." Clinical Pathology in Gastroenterology Conference, Southeastern Society of Gastroenterology Nurses, Savannah, GA, March 27, 1999.

Murphy ME. "Cirrhosis," South College Physicians' Assistant Lecture Series, April 26, 1999

Murphy ME. "Irritable Bowel Syndrome." South College Physicians' Assistant Lecture Series, April 26, 1999.

"GI Toxicity of NSAIDS." Merck COX-2 Tutorial, Savannah, Georgia, May 20, 1999

Kazsuba F, Murphy ME, Grimsley E, Tindol A. "Methemoglobinemia caused by sedation for EGD." Georgia Regional ACP Meeting, May, 1999.

Murphy ME. "Eating Disorders." GI Trends in the New Millennium, Candler Hospital (Regional GI Nurses' Meeting), March 25, 2000.

Murphy ME. "Antireflux Surgery." GI Medicine/Surgery Conference, Memorial Health University Medical Center, March 28, 2000.

Murphy ME. "Colorectal Cancer Screening." Ft. Stewart/Hinesville Colorectal Cancer Outreach, sponsored by the American Cancer Society. April 12, 2000.

Murphy ME. "Eating Disorders." Georgia Society for Gastrointestinal Nurses and Associates State Convention, Callaway Gardens, GA, September 24, 2000.

Mark Elliott Murphy M.D., FACP, AGAF
CURRICULUM VITAE

Murphy, ME. "Hepatitis C: Emerging Therapies." South Carolina Nurses' Association State Convention, Hilton Head, SC, October 6, 2000.

"GI Manifestations of Parkinson's Disease." Coastal Parkinson's Support Group, Savannah, GA, 2002.

Murphy ME. "Interferon-ribavirin versus interferon/ribavirin/amantadine in interferon-naïve hepatitis C patients. A randomized pilot study." SHINE Meeting, Orlando, Florida, Feb. 15, 2002.

Murphy ME. "Overview of Inflammatory Bowel Disease." Presented at CCFA Conference "To Infinity and Beyond: IBD in the 21st Century." Savannah, GA, April 27, 2002,

Course Director, CCFA Conference, "To Infinity and Beyond: IBD in the 21st Century." Savannah, GA, April 27, 2002.

Murphy ME. "Advances in Hepatitis C." Presented at the National SGNA Meeting (Plenary Session), Phoenix, AZ, May 18, 2002.

Murphy ME. "Inflammatory Bowel Disease." SGNA Winter Educational Conference, Savannah, GA, January 11, 2003.

Murphy ME. "Advances in Hepatitis C." Georgia Occupational Health Nurses' State Conference, Georgia Southern University, Statesboro, GA, September 25, 2003.

Murphy ME. "Nutrition in IBD." CCFA Regional Meeting, Savannah, GA; October 28, 2003.

Murphy ME. "Medical Therapy of Inflammatory Bowel Disease." Surgical Grand Rounds , Memorial Health University Medical Center, Savannah, GA , January 8, 2004.

Murphy ME. Discussion Moderator and Course Committee Member, Curtis and Elizabeth Anderson Cancer Institute Sixth Annual Cancer Congress, November 5-6, 2004

Murphy ME. "Reflux and Asthma: What's the Connection?" Community Health Forum, Candler/St. Joseph's Health System, November 8, 2004.

Murphy ME. "Testing for Liver Transplantation." St. Joseph's/Candler Liver Transplant Support Group, November 10, 2004.

Murphy ME. "Bariatric Surgery: Update for the Internist." Georgia Chapter of the American College of Physicians' Meeting, Savannah, Georgia, March 12, 2005.

Murphy ME. "Hot Topics in Digestive Diseases." OES Health Seminar, Savannah, GA , June 10, 2006.

Mark Elliott Murphy M.D., FACP, AGAF
CURRICULUM VITAE

Murphy ME, "How I Got From There to Here: GI Past, Present and Future." GSGNA Annual Meeting, Savannah, Georgia, April 1, 2006

Murphy ME. "Feel the Burn: an update in GERD." GAPA Annual State Convention, Destin, FL, July 27, 2006.

Murphy ME. "Update in IBD." Mercer University School of Medicine Conference In Digestive Diseases, Savannah, Georgia, September 29-30, 2007.

Murphy ME. "Crohn's Disease." Medical Grand Rounds, Memorial Health University Medical Center, November, 2007.

Murphy ME. "Pregnancy and Liver Disease." OB-GYN Grand Rounds, Memorial Health University Medical Center, February 2009

Murphy ME. "Ulcerative Colitis: State of the Art." Combined Med/Surg Grand Rounds, Memorial Health University Medical Center, March 2009.

Murphy ME. "Inflammatory Bowel Disease: What every patient should know." CCFA presentation, Memorial Health University Medical Center, June 16, 2009

ACTIVITIES

POSTGRADUATE:

Featured Writer in "If I Only Knew Now," published by the University of Georgia Press, 2005, 2006, 2007, 2008
Short Story "The Funeral" published in Collection, "O! Georgia!" (4th Edition), October, 2004
Deacon, First Baptist Church, Savannah, GA, 2002-2005
Participant in the Iowa Summer Writing Festival, July 21-26, 2002, July 18-20, 2003; July 11-13, 2009
Featured writer, First Baptist Church Advent Booklet 1996-present
Judge, Residents' Clinical Vignette Competition, Memorial Health University Medical Center, 1999
South College Physician's Assistant Faculty, 1999-present
Faculty Preceptor, Armstrong Atlantic State University Nurse Practitioner curriculum, 1999-2000
Member of Savannah United Way Steering Committee, 1998, 2007
Medical Director, Savannah ARC Clinical Trials Site, 1997-present
Alternate Delegate to 1998 Medical Society of Georgia convention
Savannah Area Chairman, MCG Alumni Committee, 1997-1998

Mark Elliott Murphy M.D., FACP, AGAF
CURRICULUM VITAE

Faculty in Digestive Diseases, Memorial Medical Center
Department of Internal Medicine
Residency Training Program (developed and implemented
curriculum; over 60 GI lectures given)
Course director for Senior GI elective for students from the
Medical College of Georgia and Mercer University
Medical School
Medical student physical diagnosis preceptor, UNC-Chapel
Hill

MEDICAL SCHOOL: Doctors Ought to Care (DOC) Speaker's Board
Physical Diagnosis Course Student Coordinator
Student Peer Advisor
MCG Tour Guide
Investigator, Student Judiciary Honor Court

UNDERGRADUATE: University Council Representative, College of Arts and
Sciences
Demosthenian Literary Society
Gridiron Secret Society, University of Georgia
Gamma Beta Phi Service Society (President)
Student Activities Fee Allocation Committee (Student
Chairman)
Honors Program Student Council (Vice president; Treasurer)
Red and Black staff writer (Entertainment Editor)
All-Campus Homecoming Committee (Subchairman)